MX2010004614A - Composiciones para tratamiento del mal de parkinson. - Google Patents
Composiciones para tratamiento del mal de parkinson.Info
- Publication number
- MX2010004614A MX2010004614A MX2010004614A MX2010004614A MX2010004614A MX 2010004614 A MX2010004614 A MX 2010004614A MX 2010004614 A MX2010004614 A MX 2010004614A MX 2010004614 A MX2010004614 A MX 2010004614A MX 2010004614 A MX2010004614 A MX 2010004614A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- compositions
- treating parkinson
- administration
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a tratamiento mejorado de enfermedades y trastornos del sistema nervioso central por la administración de apomorfina. En particular, la administración es por medio de inhalación pulmonar. La invención proporciona los medios para mejorar el tratamiento de un número de condiciones, incluyendo Mal de Parkinson.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0721394.5A GB0721394D0 (en) | 2007-10-31 | 2007-10-31 | Compositions for trating parkinson's disease |
PCT/GB2008/003698 WO2009056851A1 (en) | 2007-10-31 | 2008-10-31 | Compositions for treating parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010004614A true MX2010004614A (es) | 2010-05-20 |
Family
ID=38834618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004614A MX2010004614A (es) | 2007-10-31 | 2008-10-31 | Composiciones para tratamiento del mal de parkinson. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100288276A1 (es) |
EP (1) | EP2214649A1 (es) |
JP (1) | JP2011500869A (es) |
KR (1) | KR20100091970A (es) |
CN (1) | CN101932307A (es) |
AU (1) | AU2008320569B2 (es) |
BR (1) | BRPI0818799A2 (es) |
CA (1) | CA2703063A1 (es) |
GB (1) | GB0721394D0 (es) |
IL (1) | IL205153A (es) |
MX (1) | MX2010004614A (es) |
NZ (1) | NZ584622A (es) |
RU (1) | RU2484823C2 (es) |
SG (1) | SG185965A1 (es) |
WO (1) | WO2009056851A1 (es) |
ZA (1) | ZA201002751B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
SI1494732T1 (sl) | 2002-03-20 | 2008-08-31 | Mannking Corp | Inhalacijski aparat |
EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
KR101306384B1 (ko) | 2004-08-23 | 2013-09-09 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염 |
AU2006290227B2 (en) | 2005-09-14 | 2012-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
RU2403059C2 (ru) | 2006-02-22 | 2010-11-10 | Маннкайнд Корпорейшн | Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
KR101629154B1 (ko) | 2008-06-13 | 2016-06-21 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
DK2300083T3 (da) | 2008-06-20 | 2013-07-22 | Mannkind Corp | Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
MX2011009512A (es) | 2009-03-11 | 2011-11-29 | Mannkind Corp | Aparato, sistema y metodo para medir la resistencia de un inhalador. |
SG176738A1 (en) | 2009-06-12 | 2012-01-30 | Mannkind Corp | Diketopiperazine microparticles with defined specific surface areas |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
BR112012033060A2 (pt) | 2010-06-21 | 2018-02-27 | Mannkind Corp | métodos de sistema de liberação de fármaco em pó seco |
TW201304822A (zh) * | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
CN105667994B (zh) | 2011-04-01 | 2018-04-06 | 曼金德公司 | 用于药物药盒的泡罩包装 |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
CN104703584B (zh) * | 2012-02-28 | 2019-05-31 | 艾塞尤提卡控股公司 | 可吸入药物组合物 |
SG10201605800UA (en) | 2012-07-12 | 2016-09-29 | Mannkind Corp | Dry powder drug delivery system and methods |
CN105050581B (zh) * | 2012-10-22 | 2018-01-19 | 丝维塔斯治疗有限公司 | 降低左旋多巴血浆浓度的患者间可变性的方法 |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
JP6523247B2 (ja) | 2013-03-15 | 2019-05-29 | マンカインド コーポレイション | 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法 |
GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
WO2014205030A1 (en) * | 2013-06-19 | 2014-12-24 | Map Pharmaceuticals, Inc. | Pulmonary administration of rotigotine |
US20140377365A1 (en) * | 2013-06-19 | 2014-12-25 | Map Pharmaceuticals, Inc. | Sustained-release formulation of rotigotine |
CN114848614A (zh) | 2013-07-18 | 2022-08-05 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
MA43042A (fr) | 2015-09-28 | 2018-08-08 | Ever Neuro Pharma Gmbh | Composition aqueuse d'apomorphine pour une administration sous-cutanée |
EP3826620A4 (en) * | 2018-07-12 | 2023-03-08 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | INHALATION COMPOSITIONS CONTAINING DOPAMINE GONISTS |
GB201912686D0 (en) * | 2019-09-04 | 2019-10-16 | Reown Pharma Inc | Pharmaceutical composition |
WO2023242355A1 (en) | 2022-06-15 | 2023-12-21 | Ever Neuro Pharma Gmbh | Apomorphine prodrugs and uses thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4742054A (en) * | 1982-11-23 | 1988-05-03 | Naftchi Nosrat E | Treatment of mammals suffering from damage to the central nervous system |
US5292520A (en) * | 1990-09-13 | 1994-03-08 | Akzo N.V. | Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer |
EP0689438B1 (en) * | 1993-03-26 | 2003-06-04 | Franciscus Wilhelmus Henricus Maria Merkus | Pharmaceutical compositions for intranasal administration of apomorphine |
JP3310982B2 (ja) * | 1994-04-22 | 2002-08-05 | ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド | 男性の勃起機能不全を改善するための剤形及び方法 |
US6395744B1 (en) * | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
US20020165122A1 (en) * | 1994-04-22 | 2002-11-07 | Heaton Jeremy P. W. | Method and compositions for the treatment or amelioration of female sexual dysfunction |
US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
US6413496B1 (en) * | 1996-12-04 | 2002-07-02 | Biogland Ireland (R&D) Limited | Pharmaceutical compositions and devices for their administration |
US6193954B1 (en) * | 1997-03-21 | 2001-02-27 | Abbott Laboratories | Formulations for pulmonary delivery of dopamine agonists |
EP1035833B1 (en) * | 1997-12-02 | 2005-08-31 | Archimedes Development Limited | Compositions for nasal administration |
US20020002175A1 (en) * | 2000-09-19 | 2002-01-03 | Charanjit Behl | Nasal delivery of apomorphine in combination with glycol derivatives |
US6436950B1 (en) * | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
WO2001076602A1 (en) * | 2000-04-07 | 2001-10-18 | Tap Pharmaceutical Products Inc. | Apomorphine derivatives and methods for their use |
US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
SE0102036D0 (sv) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
US6514482B1 (en) * | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US20020086876A1 (en) * | 2000-11-15 | 2002-07-04 | Ruff Dustin D. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
US6528521B2 (en) * | 2000-11-15 | 2003-03-04 | Tap Pharmaceutical Products, Inc. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
BR0206402A (pt) * | 2001-01-16 | 2006-01-17 | Purdue Research Foundation | Processo de tratamento de disfunção relacionada a dopamina por administração de um agonista de receptor de dopamina d1 inteiro e sem indução de tolerância |
EP1392262A1 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
ITMI20012174A1 (it) * | 2001-10-18 | 2003-04-18 | Univ Parma | Polvere per somministrazione nasale di farmaci |
WO2004089374A1 (en) * | 2003-04-14 | 2004-10-21 | Vectura Ltd | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
CA2522158C (en) * | 2003-04-14 | 2018-03-20 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
-
2007
- 2007-10-31 GB GBGB0721394.5A patent/GB0721394D0/en not_active Ceased
-
2008
- 2008-10-31 KR KR1020107010375A patent/KR20100091970A/ko not_active Application Discontinuation
- 2008-10-31 EP EP08846120A patent/EP2214649A1/en not_active Withdrawn
- 2008-10-31 SG SG2012082087A patent/SG185965A1/en unknown
- 2008-10-31 NZ NZ584622A patent/NZ584622A/en not_active IP Right Cessation
- 2008-10-31 JP JP2010531580A patent/JP2011500869A/ja active Pending
- 2008-10-31 BR BRPI0818799 patent/BRPI0818799A2/pt not_active IP Right Cessation
- 2008-10-31 MX MX2010004614A patent/MX2010004614A/es not_active Application Discontinuation
- 2008-10-31 WO PCT/GB2008/003698 patent/WO2009056851A1/en active Application Filing
- 2008-10-31 CN CN2008801230145A patent/CN101932307A/zh active Pending
- 2008-10-31 CA CA2703063A patent/CA2703063A1/en not_active Abandoned
- 2008-10-31 AU AU2008320569A patent/AU2008320569B2/en not_active Ceased
- 2008-10-31 US US12/740,323 patent/US20100288276A1/en not_active Abandoned
- 2008-10-31 RU RU2010121827/15A patent/RU2484823C2/ru not_active IP Right Cessation
-
2010
- 2010-04-15 IL IL205153A patent/IL205153A/en not_active IP Right Cessation
- 2010-04-20 ZA ZA2010/02751A patent/ZA201002751B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2703063A1 (en) | 2009-05-07 |
IL205153A0 (en) | 2010-11-30 |
GB0721394D0 (en) | 2007-12-12 |
RU2010121827A (ru) | 2011-12-10 |
BRPI0818799A2 (pt) | 2015-04-22 |
RU2484823C2 (ru) | 2013-06-20 |
SG185965A1 (en) | 2012-12-28 |
ZA201002751B (en) | 2011-06-29 |
EP2214649A1 (en) | 2010-08-11 |
IL205153A (en) | 2014-11-30 |
AU2008320569B2 (en) | 2014-01-30 |
US20100288276A1 (en) | 2010-11-18 |
NZ584622A (en) | 2012-06-29 |
AU2008320569A1 (en) | 2009-05-07 |
JP2011500869A (ja) | 2011-01-06 |
WO2009056851A1 (en) | 2009-05-07 |
KR20100091970A (ko) | 2010-08-19 |
CN101932307A (zh) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010004614A (es) | Composiciones para tratamiento del mal de parkinson. | |
MX2012005131A (es) | Enfoques terapeuticos nuevos para tratar la enfermedad de alzheimer. | |
AU2016202421B2 (en) | Method of treating neurological conditions with cardiac glycosides | |
NZ599830A (en) | Novel kinase modulators | |
MY156777A (en) | Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof | |
MY179527A (en) | Catecholamine derivatives useful for the treatment of parkinson's disease | |
EA201301078A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
MX2010004494A (es) | Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios. | |
HK1146485A1 (es) | ||
MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
MY153062A (en) | Methods of treating gastrointestinal disorders independent of the intake of food | |
EA201071244A1 (ru) | Новые терапевтические подходы в лечении болезни альцгеймера и обусловленных ею расстройств посредством модуляции ангиогенеза | |
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
MY159562A (en) | Adipose tissue derived stromal cells for the treatment of neurological disorders | |
TN2011000437A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
GB2454615A (en) | Antidiabetic azabicyclo (3.1.0) hexan compounds | |
MX2021012184A (es) | Terapias genicas para trastornos lisosomales. | |
EA201171088A1 (ru) | Лечение дискинезии при различных расстройствах | |
MX2015006120A (es) | Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos. | |
GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
MX2013004067A (es) | Combinaciones de agonistas del receptor de serotonina para el tratamiento de transtornos de movimiento. | |
NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
BR112012009121A2 (pt) | Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central | |
UA102515C2 (ru) | Новая лекарственная форма | |
SG179203A1 (en) | Novel arylated camphenes, processes for their preparation and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |